Dupilumab for pediatric prurigo nodularis: A case report
Tahel Fachler, Sofia Maria Faitataziadou, Vered Molho‐Pessach
Abstract
Herein we report on a 9-year-old girl with recalcitrant prurigo nodularis unresponsive to multiple standard treatments. She was started on dupilumab therapy with rapid improvement in pruritus within 2 weeks and near complete regression of lesions at 3 months. Dupilumab should be considered as an off-label treatment for refractory prurigo nodularis in children.
Topics & Concepts
Prurigo nodularisDupilumabMedicineDermatologyPrurigoAtopic dermatitisDermatology and Skin DiseasesAllergic Rhinitis and SensitizationContact Dermatitis and Allergies